← back to search

Arman Altincatal

Sanofi (United States) · US
Area of research
Physiology · Immunology
Research interest
Research interests include Asthma and respiratory diseases, IL-33, ST2, and ILC Pathways, Eosinophilic Esophagitis, and Multiple Sclerosis Research Studies.
h-index
17
citations
994
works
117
NIH funding
primary concept
email

Recent publications

Association Between Baseline Fractional Exhaled Nitric Oxide and Mucus Response in Patients With Uncontrolled Moderate-To-Severe Asthma Treated With Dupilumab in the Vestige Study
American Journal of Respiratory and Critical Care Medicine 2025cited by 0position: middledoi
Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis
Neurology 2024cited by 36position: middledoi
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma
Respiratory Medicine 2024cited by 6position: middledoi
Dupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of inhaled corticosteroids dose
Allergy 2023cited by 10position: middledoi
Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction
Annals of Allergy Asthma & Immunology 2022cited by 14position: middledoi
Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of ICS dose
2022cited by 1position: middledoi
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
CNS Drugs 2021cited by 121position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Alberto Papi · Instituto de Investigación Sanitaria de Santiago5 papers (2022–2025)Juby A. Jacob‐Nara · Novartis (Switzerland)4 papers (2022–2024)Megan Hardin · University of Leicester4 papers (2022–2024) · 4 papers (2022–2024)Ian Pavord · Nuffield Orthopaedic Centre4 papers (2022–2024) · 4 papers (2022–2024)Elizabeth Laws · Sanofi (United States)4 papers (2022–2024)Mario Castro · University of Kansas Medical Center3 papers (2022–2025)Arnaud Bourdin · Conseil Régional du Languedoc-Roussillon3 papers (2022–2025)David J. Lederer · Regeneron (United States)3 papers (2022–2024)Paul J. Rowe · Novartis (Switzerland)3 papers (2022–2024)Jonathan Corren · APLA Health3 papers (2022–2024)Carl de Moor · Biogen (United States)2 papers (2021–2024)Amr Radwan · Novartis (Switzerland)2 papers (2022–2023)Christian Domingo · Novartis (Switzerland)2 papers (2022–2023)Karen Smirnakis · Biogen (United States)1 papers (2021–2021) · 1 papers (2022–2022)Robert J. Fox · Cleveland Clinic1 papers (2024–2024)Xavier Montalbán · Fundació ACE1 papers (2024–2024) · 1 papers (2022–2022)